rospective randomized clinical trials of treatment for renal artery stenosis have not shown an additional clinical benefit of stent placement over optimal medical therapy for either hypertension or chronic kidney disease. [1] [2] [3] [4] [5] [6] Increased albuminuria is often present in patients with hypertension or chronic kidney disease 7 and those with renal artery stenosis 8 and is
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November 2016 associated with an increased risk of adverse cardiovascular and renal events. 9 The impact of baseline microalbuminuria on cardiovascular, renal, and survival outcomes after renal artery revascularization is unknown. After principal component analysis revealed a high degree of variance in baseline urine albumin/creatinine ratios (uACRs), we used data from the CORAL study (Cardiovascular Outcomes in Renal Atherosclerotic Lesions), 4 a randomized multicenter clinical trial that examined renal artery stent placement for patients with renal artery stenosis and hypertension and chronic kidney disease, to examine whether the presence of baseline albuminuria had an effect on patient outcomes and stent treatment response.
Materials and Methods
This is a post hoc analysis using data from the CORAL study, 4 a multicenter, 2-arm randomized clinical trial that evaluated 931 patients with renal artery stenosis and either resistant hypertension or chronic kidney disease. There were 2 treatment groups in CORAL: optimal medical therapy (medical therapy) and optimal medical therapy plus direct stent revascularization (stent). Background medical therapy was based on published guidelines. 10, 11 Stent revascularization was done so that all renal artery stenoses ≥60% were treated. The study primary end point was a composite of myocardial infarction, hospitalization for congestive heart failure, stroke, renal replacement therapy, progressive renal insufficiency (≥30% reduction in estimated glomerular filtration rate sustained at least 60 days), and cardiovascular-or kidney disease-related death. 4 The study was approved by all participating institution review boards, and all study participants gave informed consent. The full study protocol, and a summary of changes, can be accessed at http://www.nejm.org/action/showSuppl ements?doi=10.1056%2FNEJMoa1310753&viewType=Popup&vie wClass=Suppl.
Principal component analysis 12 of CORAL study data revealed baseline uACR to be strongly associated with patient outcomes (Table  S1 in the online-only Data Supplement). Therefore, CORAL participants were stratified according to their aggregate median uACR, which was 22.5 mg/g. The population was divided into 2 (n=413 in each group) by the median uACR because it was the simplest and most convenient way to test the relationship of baseline uACR with treatment outcomes, with cohort 1 being those with baseline uACR ≤22.5 mg/g and cohort 2 being those with baseline uACR >22.5 mg/g. Other analyses were also done to test the sensitivity of the results to varying thresholds of uACR. For example, the analysis was repeated after dividing the CORAL cohort into deciles by baseline uACR. Also, we used a traditional uACR cut point for microalbuminuria, 30 mg/g, to divide the CORAL cohort into 2 groups for analysis.
As our primary analysis, the duration of freedom from the primary composite end point was calculated by treatment group for both cohorts using Kaplan-Meier analysis and compared using log-rank tests within each uACR stratum. Secondary analyses were performed for each component of the primary composite end point and for overall survival using similar methods. A test for interaction of the uACR cohort with the treatment group on time-to-primary end point over the entire study was performed using Cox proportional hazards regression with main effects of uACR stratum and treatment group and the interaction effect of uACR-by-treatment outcomes.
A generalized estimating equation ANOVA was used to compare treatments with respect to systolic blood pressure over time within each uACR cohort. This was performed to examine whether any reduction in end points by treatment group might be attributable to better systolic blood pressure control. Comparison of the number of antihypertensive medications at the last follow-up visit between treatment groups was done using ANOVA for both uACR cohorts, and the proportions taking angiotensin-converting enzyme inhibitor or angiotensin receptor blocker medications was compared using χ 2 tests. Baseline data were significantly skewed, so Spearman rank correlation was done to examine the relationship between estimated glomerular filtration rate and uACR for the entire population with baseline uACR. Interaction tests on race and sex in CORAL showed no treatment group interactions for these variables, and sex and race subgroups were not examined in this retrospective analysis. 4 All Pvalues are 2 sided; original study data were accessible by and all analyses were done by authors K.M.P., R.D., J.M., Q.G., and T.P.M., and performed using SAS v.9.1.3 (SAS Institute, Cary, NC).
In CORAL, uACRs were measured at the Biochemistry Core Laboratory at the University of Minnesota, under the direction of one of the authors (M.S.). Spot urine albumin was measured using kit reagents on the ProSpec nephelometric analyzer (Siemens, Dade Behring GMBH, Marburg, Germany). The coefficient of variation for this measurement was 5.6% at the low value (mean concentration 14 mg/L) and is unlikely to result in significant misclassification. Creatinine was measured in urine by the Roche enzymatic method (Roche Diagnostics Corporation, Indianapolis) on a Roche Modular P Chemistry Analyzer (Roche Diagnostics Corporation, Indianapolis), a method that is traceable to reference isotope dilution mass spectroscopy developed by the National Institute of Standards and Technology. The CORAL study was registered on ClinicalTrials. gov on April 19, 2004 (identifier NCT00081731).
Results
There were 931 evaluable participants enrolled in CORAL between May 2005 and January 2010 4 , and 826 had baseline uACR measured and were available for these analyses (Recruitment in the original study was stopped after 947 participants were enrolled, which was 88% of projected enrollment, by the Data Safety and Monitoring Board. Sixteen participants from 1 site were excluded from analysis because of data integrity issues). The average age of the aggregate group (n=826) was 69.3±8.9 (SD) years; 50% were women; 283 (35%) had diabetes mellitus; and 244 (30%) were smokers (Table) . In addition to higher uACR, cohort 2 had a higher incidence of primary end points during CORAL than cohort 1 (180/413 [44%] versus 110/413 [27%]). In cohort 1, the medical group had more prevalent diabetes mellitus, cigarette smoking, and prior myocardial infarction, but lower total cholesterol, higher high density lipoprotein, less prior heart failure, and less global ischemia than the stent group. Cohort 2 had a higher prevalence of diabetes mellitus, lower estimated glomerular filtration rate, higher baseline systolic blood pressure (Table) than cohort 1; however, within that cohort, baseline variables were similar between treatment groups, except more prevalent prior heart failure in the medical therapy group and higher baseline uACR in the stent group. One-hundred and five CORAL participants had missing baseline uACR values and were not included in these analyses; their baseline characteristics were similar to those without missing baseline uACR, and those without baseline uACR treated with stent had similar baseline characteristics as those treated with medical therapy alone, except that those with missing data in the medical therapy group had higher prevalence of diabetes mellitus, cigarette smoking, prior myocardial infarction, prior heart failure, and more global stenosis (Table) . There were 356 CORAL participants with either moderately (uACR≥30≤300 mg/g) or severely (uACR>300 mg/g) increased albuminuria.
There was a significant interaction between treatment group and uACR from the time to the composite primary end point (P=0.02). Participants in cohort 1 had significantly better freedom from the composite primary end point when treated with stent than with medical therapy (5-year Kaplan-Meier estimates of 73% versus 59%; P=0.02, logrank test; Figure 1 ; Figure S1 ), Figure  S2 ), freedom from progressive renal insufficiency (91% versus 77%; P=0.03; Figure S3 ), and overall survival (89% versus 76%; P≤0.01; Figure S4 ) all favored stent over medical therapy in cohort 1. None of the remaining components of the primary end point (myocardial infarction, hospitalization for congestive heart failure, stroke, and renal replacement therapy) showed statistically significant differences in outcomes by treatment group in cohort 1. There were no significant treatment group differences for either the primary composite end point or any of the individual components of the composite end point for cohort 2 ( Figure 1 ; Figures S1 through S4).
When the CORAL population was divided into 10 deciles by baseline uACR, hazard ratios favored stent placement for all of the deciles below the median uACR value (22.5 mg/g), but only 1 was statistically significant (P=0.01; Figure 2 ). The decile with the highest hazard ratio that favored medical therapy was the one immediately above the median value (22.5-34.6 mg/dL). This had an impact on the sensitivity analysis using the conventional threshold for moderately increased albuminuria (30 mg/g); the analysis using the threshold of 30 mg/g showed an insignificant trend favoring stent placement for those with baseline uACR below that threshold (P=0.08).
For cohort 1 there was no significant difference in systolic blood pressure over time between the 2 treatment groups (P=0.58; Figure 3A ), but there was a borderline significance for systolic blood pressure differences for cohort 2 favoring stent (P=0.052; Figure 3B ). The number of antihypertension medications at the last follow-up visit was similar among stent and medical groups for both the low (3.2±1.3 SD versus 3.3±1.4 SD, respectively; P=0.22) and high uACR cohorts (3.6±1.5 SD versus 3.7±1.4 SD, respectively; P=0.6). The use of angiotensin-converting enzyme inhibitors or angiotensin receptor blocker medication was similar between the stent and medical treatment groups in both cohorts; in cohort 1, 82% in the medical group (120/147) and 76% in the stent group (116/153) were taking either medication at close out (P=0.27; χ 2 ). For the entire group with baseline uACR (n=826), the correlation between baseline estimated glomerular filtration rate and baseline uACR was weak (r=0.23).
Discussion
This analysis shows that patients in the CORAL study with baseline uACR <22.5 mg/g experienced fewer cardiovascular, renal, and mortality events in the stent group compared with the medical therapy group. This was observed despite there being no difference in systolic blood pressure between treatment groups in cohort 1 and no difference in angiotensin-converting enzyme inhibitor or angiotensin receptor blocker medication use. Freedom from the primary composite end point* through 5 years of follow-up by treatment group and urine albumin/creatinine ratio (uACR) cohort. For baseline uACR≤22.5 mg/g, the 5-year freedom from event for stent vs medical groups was 73% vs 59%, P=0.02 (log-rank test), respectively. When baseline uACR >median, the 5-year freedom from event for stent vs medical groups was 47% vs 48%, P=0.38 (log-rank test), respectively. *Primary composite end point=myocardial infarction, hospitalization for congestive heart failure, stroke, renal replacement therapy, progressive renal insufficiency, (≥30% reduction in estimated glomerular filtration rate (eGFR) sustained at least 60 d), or cardiovascular-or kidney diseaserelated death. Median of albumin/creatinine ratio among all available follow-up is 22.5. Mean±SD (for continuous data) or frequency (for proportional data) in each treatment group, (n), according to baseline urine albumin/creatinine ratio (uACR; ≤ or > the median value [22.5 mg/g]). In the low baseline uACR stratum, the medical therapy group had more prevalent diabetes mellitus, cigarette smoking, and prior MI, but lower total cholesterol, higher HDL, less prior heart failure, and less global ischemia. Patients without baseline uACR not included in the analyses are presented in the last 2 columns for comparison; their baseline characteristics are comparable to those without missing baseline uACR and also comparable between treatment groups, except that those with missing data in the medical therapy group had higher prevalence of diabetes mellitus, cigarette smoking, prior MI, prior heart failure, and more global stenosis. Their exclusion from the analyses therefore shows no evidence of biasing the analyses done for those with baseline uACR in favor of stent placement. Global ischemia=bilateral renal artery stenosis or unilateral stenosis in a uninephric patient. BMI indicates body mass index; eGFR, estimated glomerular filtration rate; HDL, high-density lipoproteins; IQR, interquartile range; and MI, myocardial infarction. Although moderately increased albuminuria (uACR> 30<300 mg/g) is present in 8% to 15% of patients with hypertension, 13 and is common in those with renal artery stenosis, 8 the relationship between moderately increased albuminuria and treatment outcomes in patients undergoing renal artery stent placement has not been described. This is potentially an important issue; in the CORAL study population, 44% of participants had at least moderately increased baseline albuminuria (uACR >30 mg/g; Table) . If patients with moderately or severely increased albuminuria are predestined for a higher rate of cardiovascular events than those without, and that natural history is not modifiable by revascularization of stenotic renal arteries, then inclusion of large numbers of patients with moderate or severe albuminuria would bias studies of renal artery revascularization away from a statistically significant treatment effect and toward the null hypothesis. Similarly, if patients with uACR<22.5 mg/g benefit from stent placement, that is important from a public health standpoint, as its use could improve patient selection and outcomes for roughly half of the patients with renal artery stenosis and appropriate clinical presentations.
There is biological plausibility of the findings that patients with elevated uACR do not benefit from revascularization of stenotic renal arteries. Increased uACR can be considered a window on systemic endothelial and overall cardiovascular health.
14,15 Elevated uACR has a linear effect on cardiovascular and renal event risk that is independent from GFR, 7 and uACR≥100 mg/g is associated with double the mortality risk of a uACR of ≤5 mg/g 7 . Increased uACR is associated with microvascular damage including loss of integrity of the endothelial monolayer, systemic arteriolar intimal and medial thickening, increased oxidative stress, 16, 17 increased endothelial cell 16 and increased progression of atherosclerosis, 17 and is also associated with increased carotid artery intimal-medial thickness 18 and cardiac hypertrophy, 19 all of which may explain why increased uACR is associated with increased rates of myocardial infarction, stroke, hospitalization for congestive heart failure, cardiovascular death, and overall mortality. [20] [21] [22] [23] [24] [25] Although the uACR cutoff that showed benefit of stenting in this study, 22.5 mg/g, is lower than the usual cutoff for moderate albuminuria (uACR≥30<300 mg/g), the traditional cutoff is arbitrary, and in fact a large meta-analysis reported increased cardiovascular risk with uACR ≥10 mg/g. 23 The search for a convenient biomarker that could predict favorable outcomes from renal artery revascularization has been long and has included renal vein renin sampling, 26 captopril renography, 27 peripheral renal vein renin, 28 kidney size, 29 renal resistive index, 30 and serum brain natriuretic peptide levels, 31 but there is no consensus on an ideal biomarker and none were used to select patients for the 2 largest randomized clinical trials of renal artery stenting, CORAL and ASTRAL (Angioplasty and Stenting for Renal Artery Lesions). 3, 4 Some think that patients with the most refractory blood pressure, 32, 33 renal fractional flow reserve, 34 stenosis severity, 35 or transstenotic pressure gradients 36 benefit most from renal artery stenting. However, when examined for the CORAL study population, there were no significant differences in treatment outcomes based on severity of baseline hypertension, percent stenosis, or translesion pressure gradients. 37 Renal artery stenting is currently infrequently performed, probably because of multiple negative randomized clinical trials. Nevertheless, CORAL data suggest that those with low levels of albuminuria may in fact benefit from revascularization of renal artery stenoses, and if confirmed in a subsequent randomized clinical trial, uACR could serve as a widely available and inexpensive biomarker to screen for patients for whom renal artery revascularization may be clinically beneficial, especially for those at highest baseline risk of cardiovascular events.
Limitations
The analyses in this study were not part of the original statistical plan for the CORAL study, and no adjustments were made for multiple comparisons. This raises the possibility that the finding of improved outcomes after stent placement for those in the low uACR stratum could be attributed to sampling variability, and we caution against drawing inferences on the wider population of patients similar to those described in the CORAL study. However, uACR was identified as an important variable using principal component analysis, which is an accepted statistical technique for detecting dominant patterns in large data sets, 12 rather than by exhaustive data mining, possibly reducing the chance of type I error. The observation of multiple better cardiovascular and renal outcomes with stenting in patients with low uACR, and an improvement in overall survival, also argues against statistical noise. The number of patients in the low uACR stratum was large (n=413) and the P values for some of the end points were small (eg, <0.01), increasing the likelihood that the sample is representative of the underlying population. Conversely, the lack of significant differences in systolic blood pressure between treatment groups raises questions about the mechanism for improved outcomes for those undergoing stent placement in cohort 1.
Another limitation is that although participants were randomized to treatment groups, there are some differences in baseline characteristics in both uACR cohorts by treatment group. For example, in cohort 1, there is more prior heart failure and more global renal ischemia in the stent group (bilateral renal artery stenosis or unilateral stenosis in a uninephric patient), but fewer prior myocardial infarctions and smokers. These differences seem within the range of what is typically observed in randomized trials and do not seem to favor one treatment group over the other.
Perspectives
In this post hoc study of CORAL study data, low baseline uACR was associated with better patient outcomes in the stent group compared with the medical therapy group. Because this finding could be attributable to sampling variability, further research is needed. What Is New?
• The CORAL study (Cardiovascular Outcomes in Renal Atherosclerotic Lesions) and other randomized clinical trials have not shown any positive treatment effects of renal artery stenting. However, in this article, we report a novel observation that stents significantly improved outcomes for patients with low baseline uACRs. This finding was confirmed using the primary end point in CORAL, multiple components of the primary end point, and plus overall survival.
What Is Relevant?
• Although done without adjustment for multiple comparisons, there is statistical rigor to these observations. But, we caution against considering these results definitive. They should be examined in another study. If confirmed, this information would likely transform management of renal artery stenosis.
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